MedElevator Войти в исследования
← Поиск публикаций

DOI 10.23736/s0392-9590.21.04816-1

Медицинская библиотека · International angiology : a journal of the International Union of Angiology · 2021

Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization.

Moll Maria A, Zwerger Daniela, Grassl Kristina J, Westreicher Werner, Neururer Sabrina B, Moll Clemens W, Wipper Sabine H, Klocker Josef

СтатьяНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The VOYAGER PAD trial investigated data on dual pathway inhibition after lower limb revascularization for peripheral arterial disease (PAD). Multiple exclusion criteria were applied. However, neither data on the prevalence of exclusion criteria nor on the total number of patients screened for inclusion was discussed.

METHODS

We performed a single-center prospective observational study in unselected PAD patients undergoing lower limb revascularization. Demographic and disease-specific data was collected.

RESULTS

One hundred fifty patients were included with only 29 patients (19.3%) as potential candidates for the VOYAGER PAD study medication. Poorly controlled diabetes or severe uncontrolled hypertension (33.3%), major tissue loss (18.7%), acute limb ischaemia within prior 2 weeks (17.3%) and a history of intracranial hemorrhage, stroke or TIA (16%) were amongst the exclusion criteria most frequently met. Compared to VOYAGER PAD study patients, significant differences regarding sex (36.7% female vs. 25.8%), renal insufficiency (29.0% vs. 20.1%), previous myocardial infarction (16.7% vs. 11.1%) and known carotid artery disease (18.7% vs. 8.6%) revealed. Patients presented significantly more frequently with critical limb ischemia (56.7% vs. 30.4%) and a history of previous peripheral revascularization (72.0% vs. 35.9%). Fewer endovascular interventions (52% vs. 65.5%) and more surgeries (58% vs. 34.5%) were performed.

CONCLUSIONS

In unselected patients undergoing revascularization for peripheral arterial disease, the majority presents with characteristics that, at present, preclude prescription of rivaroxaban in addition to aspirin. This patient cohort represents a population with higher rates of comorbidities and more complex vascular interventions, but might also benefit from dual pathway inhibition strategy.

Для цитирования: Moll Maria A, Zwerger Daniela, Grassl Kristina J, Westreicher Werner, Neururer Sabrina B, Moll Clemens W, Wipper Sabine H, Klocker Josef. Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization.. International angiology : a journal of the International Union of Angiology. 2021. DOI: 10.23736/s0392-9590.21.04816-1.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.